VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Novartis AG vs Pernod Ricard SA
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Novartis AG
NOVN · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novartis AG's moat claims, evidence, and risks.
View NOVN analysisPernod Ricard SA
RI · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Pernod Ricard SA's moat claims, evidence, and risks.
View RI analysisComparison highlights
- Moat score gap: Pernod Ricard SA leads (75 / 100 vs 65 / 100 for Novartis AG).
- Segment focus: Novartis AG has 5 segments (29.3% in Oncology); Pernod Ricard SA has 3 segments (42.3% in Asia/Rest of the World).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Novartis AG has 4 moat types across 3 domains; Pernod Ricard SA has 4 across 2.
Primary market context
Novartis AG
Oncology
Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)
Global
Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels
Originator developer, manufacturer, and marketer of oncology therapies
29.3%
Pernod Ricard SA
Asia/Rest of the World
Premium spirits brand ownership, marketing, and distribution
Asia-Pacific, Africa, and other emerging markets
On-trade, off-trade, distributors, and duty-free operators
Brand owner and local-market route-to-market operator
42.3%
Side-by-side metrics
Moat coverage
Shared moat types
Novartis AG strengths
Pernod Ricard SA strengths
Segment mix
Novartis AG segments
Full profile >Cardiovascular, Renal and Metabolic
Oligopoly
Immunology
Oligopoly
Neuroscience
Oligopoly
Oncology
Oligopoly
Established Brands
Competitive
Pernod Ricard SA segments
Full profile >Europe
Oligopoly
Americas
Oligopoly
Asia/Rest of the World
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.